Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Brain and Cognition Discovery Foundation, Canada; University of Toronto, Toronto, ON, Canada.
J Affect Disord. 2021 Mar 1;282:160-164. doi: 10.1016/j.jad.2020.12.119. Epub 2020 Dec 29.
Dissociation is a treatment-emergent adverse event commonly associated with IV ketamine, often measured using the 23-item Clinician-Administered Dissociative States Scale (CADSS). The objective of this study was to develop a short form version of the CADSS for easier clinical use.
Retrospective data of 260 patients with treatment-resistant depression (TRD) receiving IV ketamine were randomly divided into two datasets. The first dataset (n = 130) was leveraged to develop a brief 6-item version of the CADSS (CADSS-6) based on items most sensitive to ketamine-induced dissociation. The CADSS-6 questions were then applied to the second dataset (n = 130) and the Spearman's correlation between the full-length CADSS and the CADSS-6 were assessed.
The CADSS-6 was developed from questions 1, 2, 6, 7, 15, and 22 from the full length CADSS. There was a strong significant correlation between the CADSS-6 total score and the CADSS total score at infusions 1 (rs(106) = 0.92, p < 0.001), 2 (rs(100) = 0.91, p < 0.001), 3(rs(99) = 0.95, p < 0.001) and 4 (rs(102) = 0.94, p < 0.001).
The CADSS-6 was developed using a retrospective data; therefore, the scale remains unvalidated in this population.
The CADSS-6 presented herein was sensitive to dissociation experienced by patients receiving IV ketamine. Overall, the CADSS-6 was strongly correlated at each infusion with the full-length CADSS. While future studies should look to validate the CADSS-6 in a TRD sample, this scale offers clinicians a brief assessment that can be used to characterize symptoms of dissociation.
分离是一种与 IV 氯胺酮治疗相关的治疗后不良事件,通常使用 23 项临床医生管理的分离状态量表(CADSS)进行测量。本研究的目的是开发 CADSS 的简短版本,以便于临床使用。
回顾性分析 260 例接受 IV 氯胺酮治疗的难治性抑郁症(TRD)患者的数据,将其随机分为两组。第一组(n=130)用于基于对氯胺酮诱导分离最敏感的项目,开发 CADSS 的简短 6 项版本(CADSS-6)。然后将 CADSS-6 问题应用于第二组(n=130),并评估全长 CADSS 与 CADSS-6 之间的 Spearman 相关性。
CADSS-6 是从全长 CADSS 的问题 1、2、6、7、15 和 22 开发而来。在输注 1(rs(106)=0.92,p <0.001)、2(rs(100)=0.91,p <0.001)、3(rs(99)=0.95,p <0.001)和 4(rs(102)=0.94,p <0.001)时,CADSS-6 总分与 CADSS 总分之间存在强烈的显著相关性。
CADSS-6 是使用回顾性数据开发的;因此,该量表在该人群中尚未得到验证。
本文提出的 CADSS-6 对接受 IV 氯胺酮治疗的患者的分离体验敏感。总体而言,CADSS-6 在每个输注过程中与全长 CADSS 高度相关。虽然未来的研究应该在 TRD 样本中验证 CADSS-6,但该量表为临床医生提供了一种简短的评估方法,可用于描述分离症状。